HeartMate 3 LVAD

With Full Maglev Flow Technology

Clinical Evidence

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.*¹ For the first time in LVAD history, 5-year data is available from this prospective randomized LVAD trial.²

View Momentum 3 Trial

HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival
exceeding
5 years

58.4%
survival at
5 years

Life-prolonging therapy in a
patient population who
otherwise would not be
expected to survive beyond 9
months^2,3**

Superiority of the HeartMate
3 LVAD driven by a reduction
in hemocompatibility- related
adverse events²

Survival comparable to
higher-risk transplant
patients^2,4

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

ELEVATE Registry

The ELEVATE Registry evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting.⁵ 5-year extended follow-up showed significant increase in 6-minute walk distance.

Significant Increase in 6-Minute Walk Distance⁵

Three silhouettes of figures walking along a football field representing the 6-minute walk test. Patients with HeartMate 3 LVAD saw over a two-fold increase in distance.

Quality-of-life improved significantly and was sustained through 5 years ⁵

As measured by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

Improved Safety Profile⁵

Stroke
10.8% in first 2 years
3.6% in years 2-5

Thrombosis
1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

Manuals & Resources

Cardiovascular Products

Customer Service

This device is commercially available for use in select international markets.

*HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Patients on inotropes who did not receive a transplant or left ventricular assist device.

References

Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022. doi:10.1001/jama.2022.16197
Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8(5):880-886.
Kilic et al. Factors associated with 5-year survival in older heart transplant recipients. J Thorac Cardiovasc Surg 2012;143:468-74.
Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. Presented at: European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.

MAT-2105164 v2.0

CARDIOVASCULAR

HeartMate 3 LVAD

With Full Maglev Flow Technology

Clinical Evidence

HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival
exceeding
5 years

58.4%
survival at
5 years

Life-prolonging therapy in a
patient population who
otherwise would not be
expected to survive beyond 9
months^2,3**

Superiority of the HeartMate
3 LVAD driven by a reduction
in hemocompatibility- related
adverse events²

Survival comparable to
higher-risk transplant
patients^2,4

ELEVATE Registry

Significant Increase in 6-Minute Walk Distance⁵

Quality-of-life improved significantly and was sustained through 5 years ⁵

As measured by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

Improved Safety Profile⁵

Stroke
10.8% in first 2 years
3.6% in years 2-5

Thrombosis
1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

This device is commercially available for use in select international markets.

References

POLICIES & ADVISORIES

HEALTHCARE PROFESSIONALS

PATIENTS & CAREGIVERS

Disclaimer

CARDIOVASCULAR

HeartMate 3 LVAD

With Full Maglev Flow Technology

Clinical Evidence

HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival exceeding 5 years

58.4% survival at 5 years

Life-prolonging therapy in a patient population who otherwise would not be expected to survive beyond 9 months2,3**

Superiority of the HeartMate 3 LVAD driven by a reduction in hemocompatibility- related adverse events2

Survival comparable to higher-risk transplant patients2,4

ELEVATE Registry

Significant Increase in 6-Minute Walk Distance5

Quality-of-life improved significantly and was sustained through 5 years 5

As measured by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

Improved Safety Profile5

Stroke 10.8% in first 2 years 3.6% in years 2-5

Thrombosis 1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

This device is commercially available for use in select international markets.

References

POLICIES & ADVISORIES

HEALTHCARE PROFESSIONALS

PATIENTS & CAREGIVERS

Disclaimer

Median survival
exceeding
5 years

58.4%
survival at
5 years

Life-prolonging therapy in a
patient population who
otherwise would not be
expected to survive beyond 9
months^2,3**

Superiority of the HeartMate
3 LVAD driven by a reduction
in hemocompatibility- related
adverse events²

Survival comparable to
higher-risk transplant
patients^2,4

Significant Increase in 6-Minute Walk Distance⁵

Quality-of-life improved significantly and was sustained through 5 years ⁵

Improved Safety Profile⁵

Stroke
10.8% in first 2 years
3.6% in years 2-5

Thrombosis
1.1% at 5 years